DGIdb - CAFFEINE Drug Record

CAFFEINE chembl:CHEMBL113 Approved

Alternate Names:

YEAST-VITE
METHYLTHEOBROMINE
CAFFEINE MELTING POINT STANDARD
NODOZ
ZANTHINE
CAFFEINE
PRO-PLUS
THEINE
CAFCIT
ANHYDROUS CAFFEINE
NSC-5036
FEMA NO. 2224
NODOZ CAPLETS AND CHEWABLE TABLETS
COFFEINE
1,3,7-TRIMETHYL-3,7-DIHYDRO-1H-PURINE-2,6-DIONE
3,7-DIHYDRO-1,3,7-TRIMETHYL-1H-PURINE-2,6-DIONE
7-METHYL THEOPHYLLINE
CAFÉINE
COFFEINUM
LANORINAL
METHYLTHEOBROMIDE
1-METHYLTHEOBROMINE
1,3,7-TRIMETHYL-2,3,6,7-TETRAHYDRO-1H-PURINE-2,6-DIONE
TEÍNA
PROPOXYPHENE
COFFEIN
7-METHYLTHEOPHYLLINE
1,3,7-TRIMETHYL-2,6-DIOXOPURINE
ANHYDROUS CAFFEINE (JP15)
THEIN
HYCOMINE
1,3,7-TRIMETHYLXANTHINE
GUARANINE
KOFFEIN
CAFEÍNA
MATEÍNA
MONOHYDRATE CAFFEINE
1-METHYL-THEOBROMINE
METHYLXANTHINE THEOPHYLLINE
1,3,7-TRIMETHYLPURINE-2,6-DIONE
CAFFEINUM
3,7-DIHYDRO-1,3,7-TRIMETHYL-1H-PURIN-2,6-DION
1,3,7-TRIMETHYLPURINE-2,6-QUINONE
chemidplus:58-08-2
rxcui:1886
drugbank:00201
pubchem.compound:2519
chembl:CHEMBL113

Drug Info:

FDA Approval	not approved by the FDA
Drug Class	small molecule
Drug Indications	Central Nervous System Stimulants
Year of Approval	not approved by the fda
Drug Class	central nervous system stimulants

(4 More Sources)

Publications:

Mustafa et al., 2006, Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?, Xenobiotica
Rieg et al., 2007, Adenosine A1 receptors determine effects of caffeine on total fluid intake but not caffeine appetite., Eur. J. Pharmacol.
Wang, 2007, Caffeine facilitation of glutamate release from rat cerebral cortex nerve terminals (synaptosomes) through activation protein kinase C pathway: an interaction with presynaptic adenosine A1 receptors., Synapse
Listos et al., Adenosine receptor antagonists intensify the benzodiazepine withdrawal signs in mice., Pharmacol Rep
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Gaytan et al., 2006, Effect of postnatal exposure to caffeine on the pattern of adenosine A1 receptor distribution in respiration-related nuclei of the rat brainstem., Auton Neurosci
Zhao et al., 2007, Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist., J. Cardiovasc. Pharmacol.
Riksen et al., 2007, The 1976C>T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo., Pharmacogenet. Genomics
Cornelis et al., 2007, Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption., Am. J. Clin. Nutr.
Domschke K et al., 2012, ADORA2A Gene variation, caffeine, and emotional processing: a multi-level interaction on startle reflex., Neuropsychopharmacology
Rogers PJ et al., 2010, Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption., Neuropsychopharmacology
Childs E et al., 2008, Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety., Neuropsychopharmacology
Rétey JV et al., 2007, A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep., Clin Pharmacol Ther
Alsene K et al., 2003, Association between A2a receptor gene polymorphisms and caffeine-induced anxiety., Neuropsychopharmacology
Ribeiro et al., 2010, Caffeine and adenosine., J. Alzheimers Dis.
Seo et al., 1999, Caffeine does not inhibit substance P-evoked intracellular Ca2+ mobilization in rat salivary acinar cells., Am. J. Physiol.
Shibuya et al., 1999, Prostaglandin E2 induces Ca2+ release from ryanodine/caffeine-sensitive stores in bovine adrenal medullary cells via EP1-like receptors., J. Neurochem.
Tohda et al., 1992, A possible involvement of DNA topoisomerase I in "caffeine effect" after ultraviolet irradiation., Tohoku J. Exp. Med.
Sidorenko et al., 2008, Ionic strength and magnesium affect the specificity of Escherichia coli and human 8-oxoguanine-DNA glycosylases., FEBS J.
Tong J et al., 1997, Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease., J Biol Chem
Kondo T et al., 2018, Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia., J Anesth
Sambuughin N et al., 2001, Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families., Neuromuscul Disord
Daly, 2007, Caffeine analogs: biomedical impact., Cell. Mol. Life Sci.
Mehiri et al., 2005, Time-based gene expression programme following diaphragm injury in a rat model., Eur. Respir. J.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Sara et al., 2004, The role of nitric oxide on contractile impairment during endotoxemia in rat diaphragm muscle., Eur. J. Pharmacol.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Kitagawa K et al., 1999, The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP., Biochem Biophys Res Commun
Wang H et al., 2011, Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes., Pharmacogenomics
Tanii H et al., 2011, Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women., Eur J Clin Pharmacol
Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
Hirose T et al., 2010, Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer., Oncol Rep
Djordjevic N et al., 2010, In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population., Eur J Clin Pharmacol
Tan L et al., 2010, The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients., Clin Neurol Neurosurg
Ishii Y et al., 2010, Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?, Cancer Chemother Pharmacol
Murai K et al., 2009, Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes., Xenobiotica
Kong SY et al., 2009, Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer., Pharmacogenomics
di Iulio J et al., 2009, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function., Pharmacogenet Genomics
Arab-Alameddine M et al., 2009, Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals., Clin Pharmacol Ther
Endo T et al., 2008, Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine., Pharmacogenet Genomics
Fujita K et al., 2008, CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1., Cancer Sci
Kaida Y et al., 2008, The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer., Clin Pharmacol Ther
Fukami T et al., 2007, A novel duplication type of CYP2A6 gene in African-American population., Drug Metab Dispos
Peamkrasatam S et al., 2006, In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais., Drug Metab Pharmacokinet
Audrain-McGovern J et al., 2007, The role of CYP2A6 in the emergence of nicotine dependence in adolescents., Pediatrics
Benowitz NL et al., 2006, CYP2A6 genotype and the metabolism and disposition kinetics of nicotine., Clin Pharmacol Ther
Nakajima M et al., 2006, Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations., Clin Pharmacol Ther
Nurfadhlina M et al., 2006, CYP2A6 polymorphisms in Malays, Chinese and Indians., Xenobiotica
Minematsu N et al., 2006, Limitation of cigarette consumption by CYP2A64, 7 and *9 polymorphisms., Eur Respir J
Malaiyandi V et al., 2006, Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy., Mol Psychiatry
Huang S et al., 2005, CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents., Pharmacogenet Genomics
Kimura M et al., 2005, Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans., Drug Metab Dispos
Gambier N et al., 2005, Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort., Pharmacogenomics J
Fukami T et al., 2005, Characterization of novel CYP2A6 polymorphic alleles (CYP2A618 and CYP2A619) that affect enzymatic activity., Drug Metab Dispos
Gyamfi MA et al., 2005, High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana., Eur J Clin Pharmacol
Fukami T et al., 2004, A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo., Clin Pharmacol Ther
Schoedel KA et al., 2004, Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians., Pharmacogenetics
Fujieda M et al., 2004, Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers., Carcinogenesis
Yamanaka H et al., 2004, Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted., Eur J Pharm Sci
Iwahashi K et al., 2004, Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior., Neuropsychobiology
Yoshida R et al., 2003, Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro., Clin Pharmacol Ther
Ando M et al., 2003, Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults., J Epidemiol
Ariyoshi N et al., 2002, Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers., Cancer Epidemiol Biomarkers Prev
Daigo S et al., 2002, A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur., Pharmacogenetics
Xu C et al., 2002, An in vivo pilot study characterizing the new CYP2A67, 8, and *10 alleles., Biochem Biophys Res Commun
Zhang X et al., 2001, Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population., Nihon Arukoru Yakubutsu Igakkai Zasshi
Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun
Tan W et al., 2001, Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population., Int J Cancer
Ariyoshi N et al., 2001, A novel single nucleotide polymorphism altering stability and activity of CYP2a6., Biochem Biophys Res Commun
Poland RE et al., 2000, Effect of cigarette smoking on coumarin metabolism in humans., Nicotine Tob Res
Rao Y et al., 2000, Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking., Mol Pharmacol
Oscarson M et al., 1999, Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism., FEBS Lett
Vigh et al., 2003, Intracellular calcium release resulting from mGluR1 receptor activation modulates GABAA currents in wide-field retinal amacrine cells: a study with caffeine., Eur. J. Neurosci.
Kunz et al., 1993, Mitochondrial oxidative phosphorylation in saponin-skinned human muscle fibers is stimulated by caffeine., FEBS Lett.
Bassani et al., 1995, CaMKII is responsible for activity-dependent acceleration of relaxation in rat ventricular myocytes., Am. J. Physiol.
Sampieri et al., 2005, The foot structure from the type 1 ryanodine receptor is required for functional coupling to store-operated channels., J. Biol. Chem.
Oppelt et al., 2004, Role of intracellular calcium stores on the effect of metabotropic glutamate receptors on phosphorylation of glial fibrillary acidic protein in hippocampal slices from immature rats., Neurochem. Res.
Sahir et al., 2004, Caffeine induces sonic hedgehog gene expression in cultured astrocytes and neurons., J. Mol. Neurosci.
Hancock et al., 1988, Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E., J. Immunol.
Rapuri et al., 2001, Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes., Am. J. Clin. Nutr.

CAFFEINE TRPC1

Interaction Score: 4.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15878845

Sources:
NCI
CAFFEINE OGG1

Interaction Score: 4.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18557781

Sources:
NCI
CAFFEINE CYP2A6

Interaction Score: 4.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10448083 21521021 21494765 20860463 20596643 20155256 20089352 19921195 19845430 19604090 19238117 19225447 18698229 18380793 18212800 17267622 17220563 17130279 17112802 16952495 16891249 16452582 16402128 16272956 15980104 15940289 15900015 15660270 15592323 15475735 15308589 15265511 14981342 12844137 12749606 12223434 12042667 11779172 11725533 11394901 11241319 11237731 11197315 10999944 10544257

Sources:
PharmGKB
CAFFEINE SHH

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15456933

Sources:
NCI
CAFFEINE LPAR2

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10199823

Sources:
NCI
CAFFEINE GRM1

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12814357

Sources:
NCI
CAFFEINE RYR1

Interaction Score: 0.95

Interaction Types & Directionality:

activator (activating)

Interaction Info:

PMIDs:
9334205 29344738 11525881 17514358

Sources:
PharmGKB
CAFFEINE ADORA2A

Interaction Score: 0.93

Interaction Types & Directionality:

multitarget

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Adenosine receptor antagonist

PMIDs:
11752352 17577101 17558310 17616786 22012471 20520601 18305461 17329997 12825092

Sources:
ChemblInteractions TEND PharmGKB TTD
CAFFEINE ADORA1

Interaction Score: 0.74

Interaction Types & Directionality:

multitarget

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Adenosine receptor antagonist

Trial Name -

PMIDs:
17162470 17126319 17372967 17085856 11752352 16702031

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
CAFFEINE PTGER1

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10537077

Sources:
NCI
CAFFEINE MYO9B

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8495738

Sources:
NCI
CAFFEINE PDE4B

Interaction Score: 0.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17514358 17016423 17139284

Sources:
TdgClinicalTrial TEND
CAFFEINE ADORA2B

Interaction Score: 0.31

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Adenosine receptor antagonist

Direct Interaction yes

Trial Name -

PMIDs:
20164566

Sources:
TdgClinicalTrial ChemblInteractions
CAFFEINE CAMK2B

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7864197

Sources:
NCI
CAFFEINE ADORA3

Interaction Score: 0.24

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Adenosine receptor antagonist

Direct Interaction yes

PMIDs:
20164566

Sources:
ChemblInteractions
CAFFEINE FGF2

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15738284

Sources:
NCI
CAFFEINE GFAP

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15260132

Sources:
NCI
CAFFEINE IL2RA

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3129507

Sources:
NCI
CAFFEINE NOS1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15556151

Sources:
NCI
CAFFEINE TOP1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1339096

Sources:
NCI
CAFFEINE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CAFFEINE VDR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11684540

Sources:
NCI
CAFFEINE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CAFFEINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CAFFEINE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CAFFEINE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CAFFEINE AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: CAFFEINE
- Version: 01-August-2011
Alternate Names:

CAFFEINE Primary Drug Name

Drug Info:

Drug Class central nervous system stimulants

Year of Approval not approved by the fda

Publications:
TdgClinicalTrial: CAFFEINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Central Nervous System Stimulants

Drug Class small molecule

FDA Approval not approved by the FDA

Publications:

NCI: CAFFEINE

Version: 14-September-2017

Alternate Names:

C328 NCI drug code

Drug Info:

Publications:

Kunz et al., 1993, Mitochondrial oxidative phosphorylation in saponin-skinned human muscle fibers is stimulated by caffeine., FEBS Lett.

Sahir et al., 2004, Caffeine induces sonic hedgehog gene expression in cultured astrocytes and neurons., J. Mol. Neurosci.

Hancock et al., 1988, Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E., J. Immunol.

DTC: CAFFEINE
- Version: 02-September-2020
Alternate Names:

CHEMBL113 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: caffeine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Tong J et al., 1997, Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease., J Biol Chem

Sambuughin N et al., 2001, Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families., Neuromuscul Disord

Kondo T et al., 2018, Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia., J Anesth

TTD: Caffeine
- Version: 2020.06.01
Alternate Names:

D0B3HD TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL113
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL113
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	Adenosine receptor antagonist

multitarget
antagonist (inhibitory)

multitarget
antagonist (inhibitory)

Trial Name	-
Novel drug target	Established target

CAFFEINE Drug Record

CAFFEINE chembl:CHEMBL113 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15878845

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18557781

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15456933

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10199823

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12814357

Sources: NCI

Interaction Types & Directionality: activator (activating)

Interaction Info:

PMIDs: 9334205 29344738 11525881 17514358

Sources: PharmGKB

Interaction Types & Directionality: multitarget antagonist (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Adenosine receptor antagonist

PMIDs: 11752352 17577101 17558310 17616786 22012471 20520601 18305461 17329997 12825092

Sources: ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: multitarget antagonist (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Adenosine receptor antagonist Trial Name -

PMIDs: 17162470 17126319 17372967 17085856 11752352 16702031

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10537077

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8495738

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 17514358 17016423 17139284

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Adenosine receptor antagonist Direct Interaction yes Trial Name -

PMIDs: 20164566

Sources: TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7864197

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Adenosine receptor antagonist Direct Interaction yes

PMIDs: 20164566

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15738284

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15260132

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3129507

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15556151

Sources: NCI

Interaction Types & Directionality:

n/a

PMIDs:
15878845

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18557781

Sources:
NCI

Interaction Types & Directionality:

n/a

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15456933

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10199823

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12814357

Sources:
NCI

Interaction Types & Directionality:

activator (activating)

PMIDs:
9334205 29344738 11525881 17514358

Sources:
PharmGKB

Interaction Types & Directionality:

multitarget

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Adenosine receptor antagonist

PMIDs:
11752352 17577101 17558310 17616786 22012471 20520601 18305461 17329997 12825092

Sources:
ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

multitarget

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Adenosine receptor antagonist

Trial Name -

PMIDs:
17162470 17126319 17372967 17085856 11752352 16702031

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
10537077

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8495738

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17514358 17016423 17139284

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Adenosine receptor antagonist

Direct Interaction yes

Trial Name -

PMIDs:
20164566

Sources:
TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
7864197

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Adenosine receptor antagonist

Direct Interaction yes

PMIDs:
20164566

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
15738284

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15260132

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
3129507

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15556151

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1339096

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11684540

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a